Multiple Sclerosis (MS), a devastating and debilitating disease of the central nervous system, affects over 350,000 Americans and over 2.5 million people worldwide. Over a period of time, a perfectly healthy person descends in a seemingly unstoppable and progressive pattern of physical limitations. Until now. Wesleyan Research Institute (WRI) researchers report success in stopping early stage MS from progressing to the point where a normal lifestyle becomes impossible.
A new research study being conducted at The Wesley Research Institute (WRI) aims to stop the progression of early active stage Multiple Sclerosis (MS) in its tracks.
They suffer from a range of debilitating symptoms including impaired gait and mobility, bladder and bowel dysfunction, cognitive and visual impairment, and profound muscle weakness.
“Current treatments for MS only reduce the progression rate of the disease. This new treatment, if successful, will actually halt the progression of MS.”
“Not only does it aim to stop MS in its tracks but it will also spare MS sufferers from weekly injections replacing them with infusions over three consecutive days every year.”
“The medication targets lymphocytes (a type of white blood cell) to decrease the inflammatory reaction responsible for the progression of MS.”
Preliminary studies have demonstrated that as a result of this medication sufferers have experienced fewer disease relapses, a decrease in the formation of central nervous system lesions and a reduction in cumulative disabilities.
